Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1795091 + Immunotherapies in Advanced Solid Tumors
NCT03447314Phase 1Completed
- Sponsor
- GSK
- Start
- Mar 2018
- Primary completion
- Jul 2020
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 1, open-label trial of GSK1795091 in solid tumor (advanced stage) and squamous cell carcinoma of the head and neck (HNSCC), sponsored by GSK. Primary endpoints: Treatment-emergent Adverse Events up to 27 months, Dose-limiting Toxicity at 42 days and 4 more. Started Mar 2018; status: completed.
02
Drugs
GSK1795091
03
Conditions
solid tumor (advanced stage)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03447314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03447314.